無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

加齢黄斑変性症 (AMD)/他の網膜疾患の治療薬の世界市場 (2018〜2028年):ウェット型/ドライ型AMD、糖尿病網膜症 (DR)、Lucentis、Eylea、Avastin、Visudyne

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne

発行 Visiongain Ltd 商品コード 290418
出版日 ページ情報 英文 171 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.12円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
加齢黄斑変性症 (AMD)/他の網膜疾患の治療薬の世界市場 (2018〜2028年):ウェット型/ドライ型AMD、糖尿病網膜症 (DR)、Lucentis、Eylea、Avastin、Visudyne Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne
出版日: 2018年05月30日 ページ情報: 英文 171 Pages
概要

世界の網膜疾患治療薬の市場規模は、2018年に148億5000万米ドルに達する、と予測されています。また、2028年にかけて大幅な成長を遂げる見通しです。

当レポートでは、加齢黄斑変性症 (AMD) をはじめとした網膜疾患のための薬剤市場について調査し、売上動向、技術動向、市場の機会とともに収益予測、部門別 (ウェット型AMD・ドライ型AMD・DR (糖尿病網膜症)) の詳細動向などをまとめて取り上げております。

Figure 4.11 Other Drugs Forecast Revenues ($bn), 2017-2028

第1章 調査概要

第2章 世界の加齢黄斑変性症 (AMD)/他の網膜疾患の市場

  • 網膜疾患とは
  • 網膜疾患の種類
  • AMD/他の網膜疾患の診断・治療方法
  • AMDの推定患者数
  • DR (糖尿病網膜症) の併発患者数
  • RVO (網膜静脈閉塞症) の推定患者数
  • 市場の急成長の見通し
  • Eyleaが最大の治療薬となる
  • Regeneronのプレゼンスの大きさ
  • 最も大きな疾病地域はどこか?

第3章 網膜疾患市場:分野別の分析

  • ウェット型AMD:現在も最大の収益源
  • ウェット型AMD:血管由来のプロセスが明確に定義された薬剤標的を提供
  • ドライ型AMD:網膜色素上皮 (RPE) 細胞へのダメージを阻止または無効にするためのアンメットニーズ
  • DR (糖尿病網膜症) :糖尿病黄斑浮腫 (DME) をターゲットとして、臨床的な関心事となる
  • Lucentis:Eylea の延長試験はその他の新刊領域における可能性を明らかに
  • 全分野の予測

第4章 AMD/他の網膜疾患の市場における認証済み製品

  • 現在の製品が今後も市場を独占するのか?
  • Lucentis:市場で第2位の治療薬
  • Eylea:首位に立っているか?
  • Avastin:正式な承認がないが最もよく使われる製品
  • Visudyne (Valeant/Novartis): 調査対象期間中は売上が減少する見込み
  • その他の製品

第5章 ウェット型AMD向け治療薬のパイプライン製品

  • 主なパイプライン候補薬
  • Fovista (Ophthotech Corporation/Novartis):次の目玉となるか?
  • パイプライン上にある、その他の成長因子の標的
  • APL-2:AMD関連の地図状萎縮 (GA) 患者の治療法の進化
  • 新たな抗VEGFR剤、または送達システムが必要となるのか?
  • 抗炎症アプローチを活性化させるための、新たな薬剤送達システム
  • ウェット型AMD治療薬の開発における、分析中の新たな標的
  • 再生医療アプローチ

第6章 ドライ型AMD市場のパイプライン製品

  • ドライ型AMDの市場で飛躍的成長を遂げるのは誰か?
  • MC-1101 (MacuCLEAR): 市場のリーダーとなるのか?
  • ACU-4429 (Acucela):治験第III相にある視覚サイクルモジュレーター
  • ドライ型AMDにおける補体阻害への大きな期待
  • コルチコステロイド:ドライ型AMDの病因における炎症の役割を標的とする
  • 神経防護作用:現代医療の至高の目標の一つ
  • 再生医療:ドライ型AMDは最大の疾病ターゲットの一つ
  • ドライ型AMDのその他の治療法

第7章 糖尿病性網膜症 (DR) 市場のパイプライン製品

  • Ozurdex/Posurdex (Allergan) :一般的なDME患者のための認可
  • Lucentis (ルセンティス) :DRのゲームチェンジャー?
  • 新たな抗VEGF剤の追加
  • DR向けに開発中のステロイド
  • DR向けに開発中のその他の製品

第8章 地域市場の分析

  • どの市場が、最も大きな成長可能性を手に入れるのか?
  • 米国:網膜疾患の主要市場
  • 日本:強力な市場可能性
  • 欧州主要5ヶ国 (EU5):人口高齢化による市場促進
  • BRIC諸国:最大の市場成長促進要因

第9章 世界のAMD/他の網膜疾患の治療薬市場における主要企業

  • Novartis AG
    • 企業概要
    • 財務分析
    • 近年の動向
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Regeneron Pharmaceuticals

第10章 産業・市場の定性分析

  • 強み
  • 弱み
  • 機会
  • 脅威
  • 社会的要因
  • 技術的要因
  • 経済的要因
  • 政治的要因

第11章 業界関係者へのインタビュー

  • Dr. Leigh J. Hsu氏 (Vice President, Corporate Development & Strategy, Lpath, Inc.)
  • Philip G. Ralston, Jr.氏 (MacuCLEAR)

第12章 結論

目次
Product Code: PHA0313

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2018-2028: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne - our new study reveals trends, R&D progress, and predicted revenues. Where is the Retinal disease therapeutic market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2028, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 171-page report provides 140 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Retinal Disease market. See how to exploit the opportunities.

Forecasts from 2018-2028 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2028 for the following submarkets:

  • Wet age-related macular degeneration (wAMD)
  • Dry AMD (dAMD)
  • Diabetic retinopathy (DR)
  • Other retinal diseases (grouped forecast)

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those eye drug revenues?

How will individual retinal medicines perform from 2018 to 2028 at world level? Our study forecasts revenues of four prominent brands:

  • Lucentis
  • Eylea
  • Avastin
  • Visudyne

Discover how high revenues can go. See what's happening, understanding the trends, challenges and opportunities.

image1

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 11 leading national markets from 2018-2028:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).

Leading companies and the potential for market growth

Our analysis forecasts that the world market for retinal drugs will reach $14.85bn in 2018. It will achieve strong revenue expansion from 2018 to 2028. Our report reveals how high sales will go over the next 10 years.

Research and development - assess innovation, trends and possibilities

There you can also investigate R&D, appraising technological, clinical and commercial possibilities.

In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:

  • Combination therapies, including neovascularisation disrupters
  • Angiogenesis inhibition by blocking pericyte recruitment
  • Anti-inflammatory mechanisms (inc. corticosteroids)
  • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
  • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:

  • Oligonucleotides and siRNA therapy
  • Anti-integrin oligopeptide treatment
  • Complement factor inhibition and serotonin modifiers
  • Angiotensin receptor blockers and converting enzyme inhibitors
  • Biosimilars and other follow-on biologicals and next generation therapeutics
  • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. World AMD and Other Disease Market, 2017

  • 2.1 What are Retinal Diseases?
  • 2.2 Types of Retinal Diseases
  • 2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
  • 2.4 Nearly 200 Million People with AMD?
  • 2.5 Over 100 Million with DR
  • 2.6 First RVO Estimates Suggest Patient Population of 16 Million
  • 2.7 Market to Make Rapid Pace to 2028
  • 2.8 Eylea Became Leading drug in the Market
  • 2.9 Regeneron the Leading Presence in the Market
  • 2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2017

  • 3.1 Wet AMD Still the Main Source of Revenue in the Market
  • 3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
    • 3.2.1 Revenue Forecasting for Wet AMD segment, 2017-2028
  • 3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
    • 3.3.1 Dry AMD Segment to Emerge in the Forecast Period
  • 3.4 DR: Coming Into Clinical Focus, with DME the Main Target
    • 3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
  • 3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
  • 3.6 Projections for All Segmzents, 2017-2028

4. Approved Products in the AMD and Other Retinal Diseases Market, 2017-2028

  • 4.1 Will the Current Products Dominate the Market Through 2028?
  • 4.2 Lucentis: Second Leading Drug in the Market
    • 4.2.1 Positive Revenue Growth Shown in Past: 2014-2017
    • 4.2.2 Shadow of Avastin Still Hangs Over Lucentis
    • 4.2.3 Lucentis/Avastin Matters
    • 4.2.4 Eylea: The Bigger Threat to Lucentis?
    • 4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
    • 4.2.6 Improving Cost and Compliance for Lucentis
    • 4.2.7 Lucentis Revenue Forecast 2017-2028
    • 4.2.8 Will Loss of Physician Goodwill Harm Lucentis' Growth?
  • 4.3 Eylea: Holds the Throne?
    • 4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
    • 4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
    • 4.3.3 First Wave of Eylea's Expansion Finally Beginning to Break?
    • 4.3.4 Eylea into DME and Other New Indications
    • 4.3.5 Eylea Revenue Forecast 2017-2028
    • 4.3.6 How Far Can Eylea's Momentum Carry It?
  • 4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
    • 4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
    • 4.4.2 Judicial Review Averted in the UK by Price Adjustment
    • 4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
    • 4.4.4 Roche and Novartis Challenge CATT's Headline Conclusions
    • 4.4.5 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
    • 4.4.6 Avastin Revenue Forecast, 2017-2028
    • 4.4.7 Will Anything Dislodge Avastin from its Central Position?
  • 4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
    • 4.5.1 Visudyne Revenue Forecast, 2017-2028
  • 4.6 Other Drugs for Macular Degeneration and Other Retinal Diseases
    • 4.6.1 Other Drugs Revenue Forecast, 2017-2028

5. Pipeline for Wet AMD Segment, 2017-2028

  • 5.1 The Leading Pipeline Candidates
  • 5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
    • 5.2.1 Three Phase 3 Trials to Confirm Fovista's Outstanding Phase 2 Results
    • 5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
    • 5.2.3 Ophthotech Partners with Novartis for Fovista
    • 5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
    • 5.2.5 The Move toward Combination Therapies
  • 5.3 Other Growth Factor Targets in the Pipeline
    • 5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
    • 5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
    • 5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
  • 5.4 APL-2: Evaluation for the treatment of patients with geographic atrophy (GA) related to AMD
    • 5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
    • 5.4.2 Binding Affinity Comparable to Eylea
  • 5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
    • 5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
    • 5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
    • 5.5.3 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
    • 5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
    • 5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
  • 5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
    • 5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
    • 5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
  • 5.7 Other Targets Under Investigation in wAMD Drug Development
    • 5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
    • 5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
    • 5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
    • 5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
    • 5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
    • 5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
    • 5.7.7 Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
    • 5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
    • 5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
  • 5.8 Regenerative Medicine Approaches
    • 5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
    • 5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
    • 5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment, 2017-2028

  • 6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
  • 6.2 MC-1101 (MacuCLEAR): Leading the Pack?
    • 6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
    • 6.2.2 Novel Endpoints in Phase 3 Study
    • 6.2.3 Can MacuCLEAR Make It?
  • 6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
    • 6.3.1 Study Result Declared in May 2016
    • 6.3.2 Other Visual Cycle Modulators
  • 6.4 High Hopes for Complement Inhibition in Dry AMD
    • 6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
    • 6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
  • 6.5 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
    • 6.5.1 Iluvien (Alimera Sciences): Study terminated
    • 6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
  • 6.6 Neuroprotection: One of Modern Medicine's Holy Grails
    • 6.6.1 Tandospirone (Alcon): Not effective in GA
    • 6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
    • 6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
    • 6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
  • 6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
    • 6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
    • 6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
    • 6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
    • 6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
    • 6.7.5 First iPSC Trial in Japan in Dry AMD Patients
    • 6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
  • 6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2017-2028

  • 7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
  • 7.2 Lucentis: The Game Changer for DR?
  • 7.3 New Anti-VEGF Additions
    • 7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
  • 7.4 Steroids in Development for DR
    • 7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
    • 7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
    • 7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
    • 7.4.4 Cortiject (Santen): Prodrug Candidate
    • 7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
  • 7.5 Other Products in Development for DR
    • 7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
    • 7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
    • 7.5.3 TriLipix (Abbott): No New Development for Promising Drug
    • 7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013

8. Regional Market Breakdown, 2017-2028

  • 8.1 Which Markets Hold the Most Revenue Growth Potential?
  • 8.2 The US: Leading Market for Retinal Diseases
  • 8.3 Japan: Strong Market Potential
  • 8.4 EU5: Ageing Populations to Drive Market Growth
  • 8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Leading Companies in Global AMD and Other Retinal Diseases Market, 2017

  • 9.1 Novartis AG
    • 9.1.1 Company Overview
    • 9.1.2 Financials
    • 9.1.3 Key News
  • 9.2 F. Hoffmann-La Roche Ltd
    • 9.2.1 Company Overview
    • 9.2.2 Financials
    • 9.2.3 Key News
  • 9.3 Bayer AG
    • 9.3.1 Company Overview
    • 9.3.2 Financials
    • 9.3.3 Key News
  • 9.4 Regeneron Pharmaceuticals
    • 9.4.1 Company Overview
    • 9.4.2 Financials
    • 9.4.3 Key News

10. Qualitative Industry and Market Analysis, 2017-2028

  • 10.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
  • 10.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
  • 10.3 Opportunities: New Markets and R&D Synergies
  • 10.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
  • 10.5 Social: Low Diagnosis, Low Compliance
  • 10.6 Technological: Innovation for the Eye
  • 10.7 Economic: Off-Label Treatment and Reimbursement Issues
  • 10.8 Political: The Demography and Diabetes Challenges

11. Research Interviews

  • 11.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
    • 11.1.1 Major Changes in AMD and Other Retinal Diseases Market
    • 11.1.2 The Landscape of Emerging Markets
    • 11.1.3 Opportunities and Plans of Marken's Network
    • 11.1.4 DR Market Opportunities
  • 11.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
    • 11.2.1 MC-1101: Progress in Clinical Trials
    • 11.2.2 MC-1101 More Effective in Early to Mid-Range AMD
    • 11.2.3 Partnerships and Expected Launch of MC-1101

12. Conclusions

  • 12.1 The Age of Lucentis: Nearing Its Conclusion?
  • 12.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
  • 12.3 Indications Outside Wet AMD to Gain in Importance
  • 12.4 Dry AMD Market Has Huge Potential
  • 12.5 Fovista Most Prominent Among the Pipeline Candidates
  • 12.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

Table of Tables

  • Table 1.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 1.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 2.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2017
  • Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2017
  • Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2017
  • Table 3.3 Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2022
  • Table 3.4 Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2028
  • Table 3.5 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2022
  • Table 3.6 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2028
  • Table 3.7 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2017-2022
  • Table 3.8 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2022-2028
  • Table 3.9 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 3.10 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 3.11 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2017, 2022 and 2028
  • Table 4.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2022
  • Table 4.4 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2028
  • Table 4.5 Lucentis: Revenue ($bn), AGR (%), 2014 & 2017
  • Table 4.6 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
  • Table 4.7 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.8 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 4.9 Eylea: U.S. Revenue ($bn), AGR (%), 2016-2017
  • Table 4.10 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.11 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 4.12 Avastin: Revenue ($bn), AGR (%), 2015-2017
  • Table 4.13 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.14 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 4.15 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.16 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 4.17 Other Drugs Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.18 Other Drugs Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 5.1 Selected R&D Pipeline for wAMD, 2017
  • Table 6.1 Selected R&D Pipeline for Dry AMD, 2017
  • Table 7.1 Selected R&D Pipeline for DR, 2017
  • Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 8.2 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2012-2028
  • Table 8.3 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 8.4 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 8.5 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 8.6 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 8.7 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 8.8 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 8.9 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 8.10 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2022-2028
  • Table 9.1 Novartis AG: Overview 2017
  • Table 9.2 Novartis Revenue ($bn) 2016, 2017
  • Table 9.3 Roche: Overview 2017
  • Table 9.4 Roche Revenue ($bn) 2016, 2017
  • Table 9.5 Bayer: Overview 2017
  • Table 9.6 Novartis Revenue ($bn) 2016, 2017
  • Table 9.7 Regeneron Pharmaceuticals: Overview 2017
  • Table 9.8 Regeneron Pharmaceuticals: Revenue ($bn) 2016, 2017
  • Table 10.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2018
  • Table 10.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2018
  • Table 10.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2017-2028

Table of Figures

  • Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2017-2028
  • Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2017
  • Figure 2.3 Market Breakdown by Company: Market Share (%), 2017
  • Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2017
  • Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2017
  • Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2017
  • Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2022
  • Figure 3.3 Wet AMD Segment Forecast: Revenue ($bn), 2017-2028
  • Figure 3.4 Dry AMD Segment Forecast: Revenue ($bn), 2017-2028
  • Figure 3.5 DR Segment Forecast: Revenue ($bn), 2017-2028
  • Figure 3.6 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2017-2028
  • Figure 3.7 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2017, 2022 and 2028
  • Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2022
  • Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2028
  • Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2022
  • Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2028
  • Figure 4.3 Market Forecast by Product: Revenue ($bn), 2017-2028
  • Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2017, 2022 and 2028
  • Figure 4.5 Lucentis: Revenues Forecast ($bn), 2017-2028
  • Figure 4.6 Eylea Forecast: Revenue ($bn), 2017-2028
  • Figure 4.7 Drivers and Restraints for Eylea, 2017
  • Figure 4.8 Avastin Forecast: Revenue ($bn), 2017-2028
  • Figure 4.9 Drivers and Restraints for Avastin, 2017
  • Figure 4.10 Visudyne Forecast: Revenues ($bn), 2017-2028
  • Figure 4.11 Other Drugs Forecast: Revenues ($bn), 2017-2028
  • Figure 8.1 Regional Breakdown: Revenue ($bn), 2017-2028
  • Figure 8.2 Regional Breakdown: Revenue ($bn), 2017, 2022 and 2028
  • Figure 8.3 Regional Market Share (%), 2017
  • Figure 8.4 Regional Market Share (%), 2022
  • Figure 8.5 Regional Market Share (%), 2028
  • Figure 8.6 US Market: Revenue ($bn), 2017-2028
  • Figure 8.7 Japan: Revenue ($bn), 2017-2028
  • Figure 8.8 EU5: Grouped Revenue ($bn), 2017-2028
  • Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2017-2028
  • Figure 8.10 EU5 Breakdown: Market Share (%), 2017
  • Figure 8.11 EU5 Breakdown: Market Share (%), 2022
  • Figure 8.12 EU5 Breakdown: Market Share (%), 2028
  • Figure 8.13 BRIC Nations Forecast: Revenue ($bn), 2017-2028
  • Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2017-2028
  • Figure 8.15 Market Share (%) within BRIC Group by Country, 2017
  • Figure 8.16 Market Share (%) within BRIC Group by Country, 2022
  • Figure 8.17 Market Share (%) within BRIC Group by Country, 2028

COMPANIES LISTED

  • Abbott
  • Acucela Pharmaceuticals
  • Alcon
  • Alimera Sciences
  • Allegro Opthalmics
  • Allergan
  • Ampio Pharmaceuticals
  • Ampio Pharmaceuticals
  • Avalanche Biotechnologies
  • Bayer Healthcare
  • Bioeq GmbH
  • Biophytis
  • Biovail Corporation
  • Bristol-Myers Squibb
  • CalTech
  • Cell Cure Neurosciences Ltd
  • Centocor
  • Chengdu Kanghong
  • Chengdu Kanghong Biotech
  • Clearside Biomedical
  • CoMentis
  • Daiichi Sankyo
  • Diffusion Pharmaceuticals
  • Eli Lilly
  • ESBATech
  • Eye Gate Pharmaceuticals
  • ForSight Vision4
  • Gene Signal
  • Genentech
  • GlaxoSmithKline
  • Hemera Biosciences
  • iCo Therapeutics
  • Icon Bioscience
  • Iconic Therapeutics
  • Janssen Pharmaceuticals
  • Jiangsu T-mab BioPharma
  • Kala Pharmaceuticals
  • LPATH
  • Lpath, Inc.
  • MacuCLEAR
  • Mateon Therapeutics
  • Medical Need
  • Merck Sharp & Dohme
  • Mesoblast
  • Mitsubishi Tanabe Pharma
  • Molecular Partners
  • MorphoSys
  • Neuron Systems
  • Neurotech
  • Novartis
  • Novo Nordisk
  • Oakwood Laboratories
  • Ocata Therapeutics (Advanced Cell Technology)
  • OHR Pharmaceutical
  • Ophthotech Corporation
  • OpRegen (Biotime)
  • Opthea
  • Ora Bio
  • Othera Pharmaceuticals
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Oxigene
  • PanOptica
  • Pfenex
  • Pfizer
  • pSivida
  • Quark
  • Regenerative Patch Technologies
  • Regeneron/Bayer
  • Regenxbio
  • ReVision Therapeutics
  • River Vision Development
  • Roche
  • RXi Pharmaceuticals
  • Sanofi
  • Santen Pharmaceutical
  • SARcode Bioscience
  • SciFluor Life Sciences
  • Senju Pharmaceutical
  • SGS Life Science Services
  • Stealth BioTherapeutics
  • StemCells
  • Stemedica Cell Technologies
  • SV Life Sciences
  • Third Rock Ventures
  • ThromboGenics
  • Tyrogenex
  • UCB
  • Valeant Pharmaceuticals
  • Vitreoretinal Technologies
  • Xcovery Vision

List of Organisations

  • Association for Research in Vision and Ophthalmology
  • Columbia University
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • International Diabetes Federation
  • Italian Competition Authority (ICA)
  • Japanese Ministry of Health, Labour and Welfare
  • Macula and Retina Institute Glendale
  • NHS
  • NICE
  • Oregon Health and Science University
  • Retinal Research Institute
  • Riken Institute
  • UK's General Medical Council
  • University College London (UCL)
  • US National Eye Institute
  • World Health Organisation (WHO)
Back to Top